Robert I. Kriebel
Keine laufenden Positionen mehr
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
James Sulat | M | 73 |
Memory Pharmaceuticals Corp.
Memory Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ. | 4 Jahre |
Philip S. Schein | M | 84 |
U.S. Bioscience, Inc.
U.S. Bioscience, Inc. BiotechnologyHealth Technology U.S. Bioscience, Inc. is a pharmaceutical company specializing in the development and commercialization of products for patients with cancer and AIDS and allied infections. The company has three products on the market. In addition to its headquarters, U.S. Bioscience has a manufacturing facility located in Nijmegen, The Netherlands, an analytical laboratory in Exton, PA, and a subsidiary near London to coordinate clinical trials in Europe. U.S. Bioscience, Inc. is headquartered in West Conshohocken, PA. | 11 Jahre |
C. Boyd Clarke | M | 74 |
U.S. Bioscience, Inc.
U.S. Bioscience, Inc. BiotechnologyHealth Technology U.S. Bioscience, Inc. is a pharmaceutical company specializing in the development and commercialization of products for patients with cancer and AIDS and allied infections. The company has three products on the market. In addition to its headquarters, U.S. Bioscience has a manufacturing facility located in Nijmegen, The Netherlands, an analytical laboratory in Exton, PA, and a subsidiary near London to coordinate clinical trials in Europe. U.S. Bioscience, Inc. is headquartered in West Conshohocken, PA.
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | 9 Jahre |
Martha Manning | F | 69 |
U.S. Bioscience, Inc.
U.S. Bioscience, Inc. BiotechnologyHealth Technology U.S. Bioscience, Inc. is a pharmaceutical company specializing in the development and commercialization of products for patients with cancer and AIDS and allied infections. The company has three products on the market. In addition to its headquarters, U.S. Bioscience has a manufacturing facility located in Nijmegen, The Netherlands, an analytical laboratory in Exton, PA, and a subsidiary near London to coordinate clinical trials in Europe. U.S. Bioscience, Inc. is headquartered in West Conshohocken, PA. | 6 Jahre |
Paul Neff | M | 72 |
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | 9 Jahre |
Walter A. Gilbert | M | 92 |
Memory Pharmaceuticals Corp.
Memory Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ. | 12 Jahre |
Russ C. McLauchlan | M | - |
U.S. Bioscience, Inc.
U.S. Bioscience, Inc. BiotechnologyHealth Technology U.S. Bioscience, Inc. is a pharmaceutical company specializing in the development and commercialization of products for patients with cancer and AIDS and allied infections. The company has three products on the market. In addition to its headquarters, U.S. Bioscience has a manufacturing facility located in Nijmegen, The Netherlands, an analytical laboratory in Exton, PA, and a subsidiary near London to coordinate clinical trials in Europe. U.S. Bioscience, Inc. is headquartered in West Conshohocken, PA. | 3 Jahre |
Jzaneen Lalani | F | 51 |
Memory Pharmaceuticals Corp.
Memory Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ. | 5 Jahre |
Axel Unterbeck | M | - |
Memory Pharmaceuticals Corp.
Memory Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ. | 7 Jahre |
Joseph M. Donabauer | M | 61 |
Memory Pharmaceuticals Corp.
Memory Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ. | 5 Jahre |
Kenneth R. Lynn | M | 70 |
U.S. Bioscience, Inc.
U.S. Bioscience, Inc. BiotechnologyHealth Technology U.S. Bioscience, Inc. is a pharmaceutical company specializing in the development and commercialization of products for patients with cancer and AIDS and allied infections. The company has three products on the market. In addition to its headquarters, U.S. Bioscience has a manufacturing facility located in Nijmegen, The Netherlands, an analytical laboratory in Exton, PA, and a subsidiary near London to coordinate clinical trials in Europe. U.S. Bioscience, Inc. is headquartered in West Conshohocken, PA. | 2 Jahre |
Peter Young | M | 74 |
Memory Pharmaceuticals Corp.
Memory Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ. | 5 Jahre |
Benjamin J. del Tito | M | 68 |
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | 2 Jahre |
Michael Meyers | M | - |
Memory Pharmaceuticals Corp.
Memory Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ. | 7 Jahre |
Jonathan Fleming | M | 66 |
Memory Pharmaceuticals Corp.
Memory Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ. | 11 Jahre |
Paul Blake | M | 76 |
Memory Pharmaceuticals Corp.
Memory Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ. | 2 Jahre |
Lesley Russell | M | 63 |
U.S. Bioscience, Inc.
U.S. Bioscience, Inc. BiotechnologyHealth Technology U.S. Bioscience, Inc. is a pharmaceutical company specializing in the development and commercialization of products for patients with cancer and AIDS and allied infections. The company has three products on the market. In addition to its headquarters, U.S. Bioscience has a manufacturing facility located in Nijmegen, The Netherlands, an analytical laboratory in Exton, PA, and a subsidiary near London to coordinate clinical trials in Europe. U.S. Bioscience, Inc. is headquartered in West Conshohocken, PA. | 3 Jahre |
Stephen R. Murray | M | 61 |
Memory Pharmaceuticals Corp.
Memory Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ. | 3 Jahre |
Leonard Patrick Gage | M | 81 |
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | 8 Jahre |
Vaughn M. Kailian | M | 79 |
Memory Pharmaceuticals Corp.
Memory Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ. | 3 Jahre |
Joseph J. Villafranca | M | 79 |
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | 3 Jahre |
Brian H. Dovey | M | 83 |
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | 7 Jahre |
Michael Patrick Smith | M | 55 |
Memory Pharmaceuticals Corp.
Memory Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ. | 3 Jahre |
Elizabeth Hamilton Seabury Wyatt | M | 76 |
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 24 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Robert I. Kriebel
- Persönliches Netzwerk